openPR Logo
Press release

Global Proto-Oncogene Market and Clinical Pipeline Insight 2024 Report

05-04-2018 11:57 AM CET | Health & Medicine

Press release from: Kuick Resarch

Global Proto-Oncogene Market and Clinical Pipeline Insight

“Global Proto Oncogene Market and Clinical Pipeline Insight 2024” report highlights:

* Oncogenes as Therapeutic Targets for Treatment
* Market Analysis of Proto Oncogene Therapeutic Drugs
* Dosage and Price Analysis of Drugs
* Patent and Approval Year Insight
* Proto Oncogene Inhibitors Clinical Pipeline by Company, Indication and Phase
* Marketed Proto Oncogene Inhibitors Clinical Insight by Company and Indication

Download Report Sample Weblink:

https://www.kuickresearch.com/report-global-proto-oncogene-market-and-clinical-pipeline-insight-2024.php

For Report Sample Contact: neeraj@kuickresearch.com

Table of Contents

1. Introduction to Proto Oncogenes
1.1 Overview
1.2 Discovery of Transmissible Cancer Gene
1.3 Products of Oncogenes

2. Activation of Proto Oncogene to Oncogenes
2.1 From Proto Oncogenes to Oncogenes
2.1.1 Gene Amplification
2.1.2 Chromosomal Translocation
2.1.3 Mutations
2.2 Hallmarks of Cancer

3. Oncogenes as Therapeutic Targets for Treatment
3.1 ERBB2 as a Target for Breast Cancer Therapy
3.2 EGFR as a Target for Colorectal Cancer Therapy
3.3 VEGF as a Target for Non-Small Cell Lung Cancer
3.4 PDGFR as a Target for Renal Cell Carcinoma

4. Prognostic and Predictive Role of Oncogenes
4.1 HER2
4.2 BRAF V600E
4.3 BCL-2
4.4 SRC

5. Market Analysis of Proto Oncogene Therapeutic Drugs
5.1 Axitinib (Inlyta)
5.2 Ponatinib (Iclusig)
5.3 Imatinib (Gleevec)
5.4 Sunitinib (Sutent)
5.5 Pazopanib (Votrient)
5.6 Dabrafenib (Tafinlar)
5.7 Vandetanib (Caprelsa)
5.8 Vemurafenib (Zelboraf)
5.9 Cabozantinib (Cabometyx and Cometriq)
5.10 Sorafenib (Nexavar)

6. Market Introduction of Proto Oncogenes
6.1 Overview
6.2 Global Sales of Proto-Oncogene Drugs
6.3 Global Proto Oncogene Protein Inhibitors Pipeline Overview

7. Global Proto Oncogene Market Dynamics
7.1 Favorable Market Parameters
7.2 Commercialization Challenges

8. Future Perspective of Proto Oncogene Market

9. Global Proto-Oncogene Protein Inhibitors Clinical Pipeline by Company, Indication and Phase
9.1 Research
9.2 Preclinical
9.3 Clinical
9.4 Phase-I
9.5 Phase-I/II
9.6 Phase-II
9.7 Phase-III
9.8 Preregistration
9.9 Registered

10. Marketed Global Proto-Oncogene Protein Inhibitors Clinical Insight by Company and Indication
10.1 Axitinib (Inlyta)
10.2 Ponatinib (Iclusig)
10.3 Imatinib (Gleevec, Glivec and Ruvise)
10.4 Lenvatinib (Kisplyx and Lenvima)
10.5 Sunitinib (Sutent)
10.6 Pazopanib (Votrient)
10.7 Dabrafenib (Tafinlar)
10.8 Vandetanib (Caprelsa, Zactima and Zictifa)
10.9 Vemurafenib (Zelboraf)
10.10 Cabozantinib (Cabometyx and Cometriq)
10.11 Nilotinib (Tasigna)
10.12 Regorafenib (Stivarga)
10.13 Dasatinib (Sprycel)
10.14 Sorafenib (Nexavar)
10.15 Crizotinib (Xalkori)
10.16 Apatinib
10.17 Omacetaxine Mepesuccinate (Synribo)
10.18 Imatinib - Pharm-Sintez (Imatib)
10.19 Phaleria Macrocarpa extract (Phalecarps)

11. Competitive Landscape
11.1 ARIAD Pharmaceuticals
11.2 AstraZeneca
11.3 Bayer Healthcare
11.4 Bristol-Myers Squibb
11.5 ChemGenex Pharmaceuticals
11.6 Dexa Medica
11.7 Eisai Pharmaceuticals
11.8 Exelixis
11.9 GlaxoSmithKline
11.10 Novartis
11.11 Onyx Pharmaceuticals
11.12 Plexxikon
11.13 Pfizer

Figure 1-1: Historical Development of Oncogenes in Various Cancer Cell Lines
Figure 1-2: Organization of the Proto Oncogene Products
Figure 2-1: Activation Methods of Oncogenes from Proto Oncogenes
Figure 2-2: Gene Amplification Step in the Conversion of Proto Oncogenes to Oncogenes
Figure 2-3: Chromosomal Translocation for the Activation Oncogene from Proto Oncogene
Figure 2-4: Classification of the Hallmarks of Cancer
Figure 3-1: Role of VEGF as a Target to Non-Small Cell Lung Cancer
Figure 3-2: PDGFR Target for the Treatment of Renal Cell Carcinoma
Figure 5-1: Axitinib- Patent Approval and Expiration Year in US
Figure 5-2: Axitinib- Patent Approval and Expiration Year in Europe
Figure 5-3: Axitinib Dosage Analysis (mg/Day)
Figure 5-4: Available Concentrations of Axitinib Oral Tablet (mg)
Figure 5-5: Inlyta- Price Analysis by Concentration (US$/Unit), 2018
Figure 5-6: Axitinib Price Analysis US$/Packet), 2018
Figure 5-7: Axitinib Treatment Cost (US$/Cycle), 2017
Figure 5-8: Ponatinib- Patent Approval Year and Expiration Year in US
Figure 5-9: Ponatinib- Patent Approval Year and Expiration Year in Europe
Figure 5-10: Iclusig Dosage Analysis (mg/Day)
Figure 5-11: Available Concentrations of Iclusig Oral Tablet Drug, mg
Figure 5-12: Iclusig- Price Analysis (US$), 2017
Figure 5-13: Imatinib- Patent Approval Year and Patent Expiration Year in US
Figure 5-14: Imatinib- Patent Approval Year and Patent Expiration Year in Europe
Figure 5-15: Imatinib Price Analysis by Concentration (US$/Unit), 2017
Figure 5-16: Imatinib Price Analysis by Concentration (US$/Packet), 2017
Figure 5-17: Sunitinib- Patent Approval Year and Expiration Year in US
Figure 5-18: Sunitinib- Patent Approval Year and Expiration Year in Europe
Figure 5-19: Available Concentrations of Sunitinib Drug, mg
Figure 5-20: Sutent Capsule Price by Concentration (US$/Unit), 2017
Figure 5-21: Sunitinib- Price Analysis by Concentration (US$/Packet), 2017
Figure 5-22: Pazopanib- Patent Approval Year and Patent Expiration Year in US
Figure 5-23: Pazopanib- Patent Approval Year and Patent Expiration Year in Europe
Figure 5-24: Pazopanib Dosage Analysis (mg/Day)
Figure 5-25: Pazopanib Price Analysis by Quantity (US$), 2017
Figure 5-26: Dabrafenib- Patent Approval and Expiration Year in US
Figure 5-27: Dabrafenib- Patent Approval and Expiration Year in Europe
Figure 5-28: Dabrafenib Dosage Analysis (mg/Day)
Figure 5-29: Available Concentration of Dabrafenib Drug, mg
Figure 5-30: Dabrafenib Price Analysis by Concentration (US$/Unit), 2017
Figure 5-31: Tafinlar Capsule Average Price Analysis by Concentration (US$/120 Capsules), 2017
Figure 5-32: Vandetanib- Patent Approval and Expiration Year in US
Figure 5-33: Vandetanib- Patent Approval and Expiration Year in Europe
Figure 5-34: Vandetanib Dosage Analysis (mg/Day)
Figure 5-35: Available Concentrations of Vandetanib Drug, mg
Figure 5-36: Vandetanib Price Analysis (US$/Unit), 2017
Figure 5-37: Vandetanib- Drug Cost (US$) in Concentration of 100 mg and 300 mg for 30 Tablets, 2017
Figure 5-38: Vemurafenib- Patent Approval Year and Expiration Year in US and Europe
Figure 5-39: Vemurafenib- Patent Approval Year and Expiration Year in Europe
Figure 5-40: Vemurafenib Dosage Analysis (mg/Day)
Figure 5-41: Vemurafenib- Market Cost of Drug (US$) for 112 Tablets and Per Unit Cost, 2017
Figure 5-42: Cabozantinib- Patent Approval Year and Expiration Year in US
Figure 5-43: Cabozantinib- Patent Approval Year and Expiration Year in Europe
Figure 5-44: Cabozantinib Dosage Analysis (mg/Day)
Figure 5-45: Available Concentrations of Cabozantinib Oral Tablet, mg
Figure 5-46: Available Drug Concentrations of Cometriq Oral Capsule, mg
Figure 5-47: Cabozantinib- Drug Cost of 20mg Concentration (US$) for 30 Tablets and Per Unit Dose, 2017
Figure 5-48: Cost of Cometriq Capsules for the Supply of 50 Capsules of Different Concentrations, (US$)
Figure 5-49: Sorafenib- Patent Approval Year and Expiration Year in US
Figure 5-50: Sorafenib- Patent Approval Year and Expiration Year in Europe
Figure 5-51: Sorafenib- Drug Cost for 120 Tablets and Per Unit Dose (US$), 2017
Figure 6-1: Global- Axitinib Drug Sales (US$ Million), 2015 and 2016
Figure 6-2: Iclusig - Sales (US$ Million), 2015
Figure 6-3: Iclusig - Sales (US$), 2016 and 2017
Figure 6-4: Global- Sales Revenue of Sunitinib Drug (US$ Billion), 2015 and 2016
Figure 6-5: Global- Sales of Pazopanib Drug (US$ Million), 2015 and 2016
Figure 6-6: Global- Sales Revenue of Vemurafenib Drug (US$ Million), 2015 and 2016
Figure 6-7: Global- Sales of Imatinib (US$ Billion), 2014-2017
Figure 6-8: Global Sales of Dabrafenib Drug (US$ Million), 2015 and 2016
Figure 6-9: Global Sales Revenue of Sorafenib Drug (US$ Million), 2014-2016
Figure 6-10: Cabozantinib (Cabometyx and Cometriq) andndash; Sales (US$ Million), 2016 and 2017*
Figure 6-11: Cabometyx and Cometriq andndash; Sales (US$ Million), 2016 and 2017*
Figure 6-12: Global Proto Oncogene Protein Inhibitors Clinical Pipeline by Phase (%), 2017 till 2024
Figure 6-13: Global Proto-Oncogene Protein Inhibitors Clinical Pipeline by Phase (Number), 2017 till 2024
Figure 7-1: Favorable Factors which Promote the Market Growth of Proto Oncogenes
Figure 7-2: Challenges to the Market Growth of Proto Oncogenes
Figure 8-1: Frontiers for the Inhibition of Cancer Development by Active Oncogenes






Table 3-1: Possible Ways to Overcome ErBb2 Mediated Chemoresistance
Table 3-2: Components of EGFR Signaling Pathway Important in Colorectal Cancer
Table 4-1: Role of Cancer Oncogene as Predictive and Prognostic Biomarker
Table 5-1: Imatinib Dosage for Various Indications (mg/Day and mg/m2/Day)
Table 5-2: Cost Effective Analysis of Imatinib Drug
Table 5-3: Clinical Efficacy Results of Sunitinib Drug in Cancer Treatment
Table 5-4: Clinical Efficacy Results of Pazopanib Drug in Cancer Treatment
Table 5-5: Clinical Effective Analysis of Dabrafenib Drug
Table 5-6: Clinical Effective Analysis of Vandetanib Drug
Table 5-7: Clinical Efficacy of Vemurafenib Drug in Cancer Treatment

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
L29 - L34, First Floor
Block L,Connaught Place
New Delhi-110001
+91-11-47067990

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Proto-Oncogene Market and Clinical Pipeline Insight 2024 Report here

News-ID: 1039549 • Views: 315

More Releases from Kuick Resarch

Lumakras Drug Clinical Insight and Sales Forecast 2026
"Lumakras Drug Clinical Insight and Sales Forecast 2026" Report Highlights: * NSCLC Targeting Lumakras Market Opportunity (US$ Million) * Colorectal Cancer Targeting Lumakras Market Opportunity (US$ Million) * Pharmacokinetics of Lumakras (Sotorasib) * Dosage, Patent and Price Analysis * Lumakras Ongoing Clinical Trials * Global KRAS Protein Inhibitors Clinical Trials Download Report: https://www.kuickresearch.com/report-lumakras-sotorasib-sales-forecast-fda-approved-kras-inhibitor-clinical-trials-non-small-cell-lung-cancer-nslc-g12c-mutation-c30h30f2n6o3-ras-gtpase The rising burden of cancer and the increasing cancer mortality rates possesses an unmet need for the development of novel therapies in the management
Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026
"Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026" Report Highlights: * Global EZH2 Inhibitor Market Opportunity > US$ 1.2 Billion by 2026 * Tazverik (Tazemetostat) First Approved EZH2 Inhibitor Drug * Dosage, Price and Sales Analysis of Tazverik * Tazverik Sales Opportunity > US$ 900 Million by 2026 * Tazverik Sales Forecast 2021 Till 2026 * EZH2 Inhibitor Clinical Pipeline Overview By Company, Indication and Phase * EZH2 Inhibitor in Clinical Trials: 7 Drugs Download
Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Tr …
"Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Trials Insight 2028" Report Highlights: * Global Bispecific Antibody Market Opportunity: > US$ 20 Billion * Global Bispecific Antibody Market Growth Rate: 100% CAGR (2016 -2021) * Approved Bispecific Antibodies In Market: 4 Antibodies * Detailed Market Sales and Trends Insight Till 2028 * Quarterly and Yearly Sales Insight Of Approved Antibodies Till Q1 2022 * Global and Regional Market Analysis * Approved Drug Sales
Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and C …
"Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and Clinical Trials Insight 2026" Report Highlights: * Global FGFR Inhibitors Market Opportunity: > USD 4 Billion by 2026 * Role of FGFR Inhibitors in Cancer Therapy * Global FGFR Market Assessment (US$) by Region and Cancer Type Clinical and Sales Insight on Approved FGFR Inhibitors: 3 (Belvesra, Pemazyre and Truseltiq) * Dosage and Drug Price Insight on Approved FGFR Inhibitors * Comprehensive Clinical Trials Insight

All 5 Releases


More Releases for Figure

THE WORLD'S MOST CONTROVERSIAL ACTION FIGURE...EVER!
FOR IMMEDIATE RELEASE THE WORLD'S MOST CONTROVERSIAL ACTION FIGURE...EVER! Contact: William Hirsch - Schlock Toys @ +1-949-677-9353 or DocSchlock@SchlockToys.com Featured on Tomi with Fox News host Tomi Lahren! SCHLOCK TOYS join forces with Kickstarter to Make Toys Great Again! The Kickstarter campaign page can be found HERE: https://www.kickstarter.com/projects/schlocktoys/collectors-edition-talking-trump-2020-man-of-action-figure/description “What a great message to be sent, and I think Trump himself would love this and that he’d be excited about it!” - Tomi Lahren, Fox News “You
Global Leisure Boats Market Dynamic, Value, Figure, Forecast 2018-2025
Qyresearchreports include new market research report Global Leisure Boats Market Professional Survey Report 2018 to its huge collection of research reports. This report studies Leisure Boats in Global market,especially in North America,China,Europe,Southeast Asia,Japan and India,with production,revenue,consumption,import and export in these regions,from 2013 to 2018,and forecast to 2025. This report focuses on top manufacturers in global market,with production,price,revenue and market share for each manufacturer,covering Riva Sunseeker Ferretti Lurssen Azimut Wally Princess Pershing Free Sample of this report is available upon request @
Global Protective Packaging Market Dynamic, Value, Figure, Forecast 2018-2025
Qyresearchreports include new market research report Global Protective Packaging Market Professional Survey Report 2018 to its huge collection of research reports. This report studies Protective Packaging in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2013 to 2018, and forecast to 2025. This report focuses on top manufacturers in global market, with production, price, revenue and
Lawn Mower Market Dynamic, Value, Figure, Forecast 2018-2025
Qyresearchreports include new market research report 2018-2025 Lawn Mower Report on Global and United States Market, Status and Forecast, by Players, Types and Applications to its huge collection of research reports. This report studies the Lawn Mower market status and outlook of global and United States, from angles of players, regions, product types and end industries; this report analyzes the top players in global and United States market, and splits the
Glissandra Skincare Proudly Supports World Figure Skating Champion, Patrick Chan
Glissandra Skincare is honoured to have participated in the World Chinese Business Association of Canada’s 2012 Fundraising Dinner to support Patrick Chan. Vancouver, BC, Canada, February 21, 2012 -- On Saturday, February 18, 2012, hundreds of guests packed the Victoria Chinese Restaurant in Downtown Vancouver to celebrate Canadian figure skater, Patrick Chan. The event was hosted by the World Chinese Business Association of Canada and raised almost $60,000 to assist in
Personal injury solicitors help client to reach five-figure settlement
Fentons Solicitors LLP, one of the UK's leading personal injury solicitors, has achieved a five-figure settlement victory for a client that suffered multiple severe injuries when the car he was a passenger in struck a line of parked cars. The 48-year old former hod-carrier was a front seat passenger when the driver lost control of the car and collided with a number of stationary vehicles. Fentons helped him to reach an